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Recent data indicate that isomerisation to all-trans retinoic acid (ATRA) is the key mechanism underlying the favourable clinical properties
of 13-cis retinoic acid (13cisRA) in the treatment of neuroblastoma. Retinoic acid (RA) metabolism is thought to contribute to resistance,
and strategies to modulate this may increase the clinical efficacy of 13cisRA. The aim of this study was to test the hypothesis that retinoids,
such as acitretin, which bind preferentially to cellular retinoic acid binding proteins (CRABPs), or specific inhibitors of the RA hydroxylase
CYP26, such as R116010, can increase the intracellular availability of ATRA. Incubation of SH-SY5Y cells with acitretin (50mM)o rR 1 1 6 0 1 0
(1 or 10mM) in combination with either 10mM ATRA or 13cisRA induced a selective increase in intracellular levels of ATRA, while
13cisRA levels were unaffected. CRABP was induced in SH-SY5Y cells in response to RA. In contrast, acitretin had no significant effect on
intracellular retinoid concentrations in those neuroblastoma cell lines that showed little or no induction of CRABP after RA treatment.
Both ATRA and 13cisRA dramatically induced the expression of CYP26A1 in SH-SY5Y cells, and treatment with R116010, but not
acitretin, potentiated the RA-induced expression of a reporter gene and CYP26A1. The response of neuroblastoma cells to R116010 was
consistent with inhibition of CYP26, indicating that inhibition of RA metabolism may further optimise retinoid treatment in neuroblastoma.
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Retinoic acid (RA) plays an important role in the growth and
differentiation of a variety of cell types, and can reverse malignant
growth in vitro and in vivo. Retinoic acid or synthetic analogues have
been used with some success as chemotherapeutic agents, particu-
larly in the treatment of neuroblastoma (NBL) (Reynolds et al, 2003).
Neuroblastoma is the most common extracranial malignant
solid tumour of childhood, and cure rates, especially for stages 3
and 4, remain low. Studies comparing the activity of 13-cis retinoic
acid (13cisRA) and all-trans retinoic acid (ATRA) in NBL cell lines
have demonstrated similar potency of these retinoids, in terms of
cellular differentiation, growth arrest and regulation of markers
such as MYCN (Thiele et al, 1985; Reynolds et al, 1994; Veal et al,
2002). The unfavourable pharmacokinetic properties of ATRA
have limited its use in the treatment of NBL (Reynolds et al, 2003).
In contrast, peak drug levels achieved in NBL patients receiving
13cisRA given as high-dose pulse therapy have been shown to be
above the 5mM concentration required to inhibit the growth of
NBL cells in vitro (Villablanca et al, 1995). A further trial showed
that 13cisRA improved event-free survival in advanced stage NBL
patients when given after either autologous bone marrow
transplantation (ABMT) or nonmyeloablative therapy, that is, in
a setting of minimal residual disease; however, approximately 50%
of patients develop resistance or are unresponsive to 13cisRA
therapy (Matthay et al, 1999).
Several lines of evidence suggest that 13cisRA acts as a prodrug
for ATRA. 13cisRA has a much lower binding affinity than ATRA
for the retinoic acid receptor (RAR) family of ligand-activated
transcription factors (A ˚strom et al, 1990; Allenby et al, 1993; Idres
et al, 2002). Furthermore, intracellular accumulation of ATRA after
incubation with 13cisRA and a delayed response to 13cisRA
compared to ATRA is seen in both NBL and sebocyte cell lines, and
in a human NBL xenograft model, supporting this hypothesis
(Tsukada et al, 2000; Ponthan et al, 2001; Veal et al, 2002). Little is
known about the mechanisms of RA isomerisation in vivo,
although a role for thiol groups has been suggested (Lanvers
et al, 1998).
Metabolism may also be important in maintaining effective
ATRA levels. Retinoic acid can be oxidised by cytochrome P450
enzymes to less active metabolites including 4-oxo-RA, 4-OH-RA,
18-OH-RA and 5,6-epoxy-RA (Marill et al, 2000, 2002). Novel RA-
inducible P450s, termed P450RAIs or CYP26s, have recently been
characterized, which have high specificity for ATRA (White et al,
1996, 2000; Tahayato et al, 2003). Cells transfected with full-length
CYP26 accumulate polar metabolites, suggesting that CYP26
isoforms play an important role in ATRA metabolism. Moreover,
a clear relationship between induction of RA metabolism and
progressive clinical resistance to RA has been demonstrated in
acute promyelocytic leukaemia patients (Muindi et al, 1992). A
novel inhibitor of RA metabolism, R116010, has recently been
shown to inhibit the oxidation of ATRA, enhance the biological
activity of ATRA in vitro and exhibit antitumour activity in vivo
(Van heusden et al, 2002).
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sThe metabolism of ATRA is also thought to be regulated by
cellular retinoic acid binding proteins (CRABPs), which may be
involved in the cellular transport of ATRA (Dong et al, 1999).
Induction of CRABPs has been reported in a number of cell lines in
response to RA (Redfern et al, 1994; Plum and Clagett-Dame,
1995). Cellular retinoic acid binding protein I has a higher affinity
for ATRA than that of CRABP II and the rate of ATRA metabolism
in isolated microsomes is faster in the presence of CRABP I than
without, suggesting a direct role for CRABP I in ATRA metabolism
(Fiorella and Napoli, 1991; Fogh et al, 1993). Furthermore, the rate
of formation of polar metabolites of RA in intact cells is
determined by the level of CRABP I (Boylan and Gudas, 1992).
On this basis, cellular retinoic acid binding protein I appears to
facilitate retinoid degradation. Acitretin is an analogue of RA used
clinically to treat psoriasis and malignant skin disorders (McNa-
mara et al, 2002; Geiger, 2003); it has a high affinity for both
CRABP I and II, but unlike ATRA, acitretin has a much lower
affinity for the RARs. Acitretin is known to increase the occupancy
of the RAR-transcription complex with ATRA by displacement of
ATRA from CRABPs (Tian et al, 1997), and it has been proposed
that the responsiveness of tissue culture cell lines to acitretin may
correlate with CRABP expression.
Although the catabolism of ATRA and 13cisRA potentially limits
clinical use, agents that inhibit ATRA metabolism, such as acitretin
or CYP26 inhibitors, may increase its biological availability and
directly affect the efficacy of retinoid treatment. Therefore, to
facilitate the continued development of RA for NBL therapy, the
aim of this study was to test the hypothesis that acitretin and
R116010 increase the retinoid response of NBL cells to treatment
with ATRA or 13cisRA.
MATERIALS AND METHODS
Cell lines
SH-SY5Y, SH-EP (N- and S-type cells, respectively, derived from
the parental line SK N SH), IMR-32 and NGP NBL cell lines were
cultured routinely in RPMI 1640 medium containing foetal calf
serum (10%), L-glutamine (2mM), penicillin (100Uml
 1) and
streptomycin (100mgml
 1). Cells were grown at 371Ci na
humidified incubator containing 5% CO2 and routinely tested
negative for mycoplasma.
Chemicals
Retinoic acid isomers were purchased from Sigma (Poole, UK).
Acitretin (Ro 10-1670) was generously provided by Hoffmann-La
Roche, Basal, Switzerland. HPLC grade n-hexane, glacial acetic
acid and propan-2-ol were from Fisher Scientific (Loughborough,
UK). Protease inhibitor cocktail was from Roche (Lewes, UK).
R116010 was a gift from Barrier Therapeutics Inc. (Princeton, NJ,
USA).
Retinoid treatment
Retinoids were dissolved in dimethyl sulphoxide (DMSO) and
diluted in cell culture medium to obtain final concentrations of
10
 10–10
 4 M. The final concentration of DMSO in all experiments
never exceeded 0.2%. All experiments were performed in dim light
and tubes containing retinoids were wrapped in aluminium foil.
Extraction of retinoids
Cell pellets were resuspended in 2ml cell culture medium and
disrupted by passage several times through a hypodermic needle
(25G 1in, 0.5mm 25mm; Terumo, Somerset, NJ, USA).
Proteins were precipitated by adding 500ml ethanol and 500ml
saturated ammonium sulphate solution to 2ml of extracellular
medium or resuspended cells. Samples were vortex mixed and
retinoids extracted into n-hexane, dichloromethane and propan-2-
ol (80:19:1) on a rotary mixer for 8min. After centrifugation at
2000g for 30min at 41C, the organic layer was removed,
evaporated under a stream of nitrogen and analysed by HPLC
(detection limits 0.02–4mgml
 1) (Veal et al, 2002).
HPLC analysis
Samples were reconstituted in 200ml mobile phase A and intra-
and extracellular retinoid levels were quantified by HPLC analysis
using a Waters 2690 Separations Module and 996 Photodiode array
(PDA) detector (Waters Ltd., Elstree, UK), with Waters Millen-
nium software for data acquisition, as described previously (Veal
et al, 2002). Cell volumes were determined as described previously
(Lu et al, 2000) and RA concentrations converted from mgml
 1
lysate to mM intracellular concentrations (Veal et al, 2002).
Preparation of cell extracts for western blotting
Cells were washed three times with ice-cold phosphate-buffered
saline and scraped into extraction buffer (100mM Tris-HCl, pH 7.4,
100mM KCl, 2mM EDTA, 25mM KF, 0.1% (v/v) Triton X-100, 1mM
benzamidine, 0.1mM Na3VO4,1 mgml
 1 pepstatin, and complete
protease inhibitor cocktail), transferred to 1.5ml Eppendorf tubes,
and immediately frozen in liquid nitrogen. Prior to analysis,
samples were thawed and dispersed by sonication for 1min, and
the protein concentration determined by a dye-binding method
(Bradford, 1976).
Western blot analysis
Whole-cell extracts (10mg of protein) were loaded onto poly-
acrylamide gels, electrophoresed, and blotted onto polyvinylidene
difluoride membranes (PVDF, Bio-Rad, Hemel Hempstead, UK).
Membranes were blocked with 5% nonfat milk in Tris-buffered
saline (TBS), pH 7.6, 0.1% Tween 20 (TBS-T), then incubated with
antibodies to CRABP I (S-14) or CRABP II (K-13) (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) or b-actin (Sigma, Poole,
UK). The antibody to CRABP I was generated from a peptide
corresponding to an internal region of human CRABP I.
Membranes were incubated with biotin-labelled anti-goat IgG
followed by streptavidin-linked horseradish peroxidase (HRP)
(Amersham Biosciences, Chalfont St Giles, UK) at 1:1000 dilution,
or HRP-coupled anti-mouse IgG (Upstate Ltd, Milton Keynes, UK)
at 1:15000 dilution for 1h at room temperature. Each step was
followed by at least four 10-min washes in TBS-T. ECL-plus
detection was carried out according to the manufacturer’s
instructions (Amersham Biosciences) and band intensity analysed
by phosphorimager (Storm 860).
Cell proliferation studies
Cells were seeded in 96-well plates at a density of 2500 cellswell
 1
and allowed to attach overnight. 13-cis retinoic acid, ATRA,
acitretin or R116010 were added to a final concentration of 0.01–
100mM. Growth was determined after 6 days using the SRB assay as
described previously (Skehan et al, 1990). Briefly, cells were fixed
with 10% trichloroacetic acid (TCA) and stained with 0.4%
sulphorhodamine B (SRB) in 1% acetic acid for 30min. Protein-
bound dye was extracted with 10mM Tris (unbuffered) and
absorption measured at 570nm.
Transient cell transfections for transactivation studies
The day before transfection, cells were seeded into 24-well culture
plates at a density of 6.5 10
4 cells per well. Cells were
cotransfected, using FuGENE 6 reagent (Roche, Lewes, UK)
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saccording to the manufacturer’s instructions, with 0.4mgo f
reporter vector pTA-RARE-SEAP or the pTA-SEAP negative
control vector (BD Biosciences Clontech, Oxford, UK), and 0.1mg
pGL3 vector that encodes the Photinus pyralis luciferase (Promega,
Southampton, UK) as an internal control to normalise for
variations in transfection efficiency. At 24h after transfection,
cells were treated with the appropriate retinoid at the indicated
concentrations and times. SEAP (Applied Biosystems, Warrington,
UK) and luciferase (Promega) detection were carried out according
to the manufacturer’s instructions.
Reverse-transcriptase polymerase chain reaction
Total RNA was isolated using the RNeasy Mini Kit including
DNase digestion (Qiagen, Crawley, UK). Reverse transcriptase
polymerase chain reaction (RT–PCR) was performed using the
Access RT–PCR kit (Promega) with primers for CYP26A1 (Kim
et al, 2002) or b-actin (sense 50-GGCATCCTCACCCTGAAGTA-30;
antisense 50-GATCTGGGTCATCTTCTCGC-30). In all, 0.5mg (for
CYP26A1 amplification) or 0.005mg (for b-actin amplification)
RNA was used in each reaction and 40 cycles of PCR were
performed under the following conditions: 941C, 30sec; 651C,
1min; 721C, 2min; and a final extension step at 721C, 7min. Under
these conditions, the PCR reactions were within the linear range
for amplification of CYP26A1 and b-actin, respectively. Control
reactions (no RNA, no reverse transcriptase) were performed
according to the manufacturer’s instructions, and the CYP26A1
PCR product was sequenced to confirm identity. PCR products
were separated on a 2% (w/v) agarose gel, and visualized by UV
light illumination after ethidium bromide staining.
Real-time PCR – CYP26A1
RNA was reverse-transcribed using Promega’s Reverse Transcrip-
tion System according to the manufacturer’s instructions, using
random hexamer primers. Real-time PCR was performed on 20ng
cDNA using TaqMan Assays-on-Demand Gene Expression pro-
ducts for human CYP26A1 in combination with the TaqMan
Universal PCR master mix (Applied Biosystems). Appropriate
controls for nonspecific amplification and contamination were
included. A GeneAmp 5700 Sequence Detection System was used
for real-time PCR amplification. As internal standard, b-actin was
measured simultaneously using the endogenous control assay
provided by Applied Biosystems. PCR amplification procedures
followed manufacturer’s instructions. Briefly, the thermocycling
program consisted of one cycle at 501C for 2min followed by 951C
for 10min and 40 cycles at 951C (15s) and 601C (1min). The data
were analysed using the GeneAmp Sequence Detection System
software.
Statistical analysis
Analysis was performed using ANOVA or t-tests. For experiments
involving measurements of retinoid concentrations or SEAP
activation, the variance increased in proportion to the mean and
statistical analysis was therefore performed after log transforma-
tion of the data. For specific comparisons (hypothesis tests)
between treatments, Bonferroni correction (Bland, 2000) was used
to maintain an experiment-wise probability for significance of
0.05. Linear contrasts were used to test for dose–response
relationships within the ANOVA models.
RESULTS
Effect of acitretin on intracellular retinoid concentrations
SH-SY5Y, SH-EP and IMR-32 NBL cells were treated with ATRA or
13cisRA (10mM) for 24h. The RA isomer present initially was the
predominant isomer observed following 24h incubation, as
demonstrated in SH-SY5Y cells (Figure 1). Concentrations of total
intracellular retinoids were lower after incubation with 13cisRA
than after incubation with ATRA, suggesting isomer-specific
uptake.
Preincubation for 24h with a range of acitretin concentrations
prior to RA incubation for a further 24h, significantly increased
intracellular ATRA concentrations in SH-SY5Y cells incubated
with ATRA (one-way ANOVA, F3,15¼3.9, P¼0.03): acitretin
concentrations of 10 and 50mM significantly increased intracellular
ATRA levels relative to controls without acitretin, from 39.177.4
(mean7s.e.m.) mM with ATRA alone to 115.7735.5mM in the
presence of 10mM acitretin and 113.5728.7mM with 50mM acitretin,
respectively (Figure 1A) (F1,15X7.2, Pp0.017, significant at
Pp0.05 after Bonferroni correction). For cells incubated with
13cisRA, 50mM acitretin significantly increased intracellular ATRA
levels relative to controls without acitretin, from 4.271.1mM with
13cisRA alone to 19.374.1mM (Figure 1B) (F1,13¼10.503,
P¼0.006). Conversely there was no effect of acitretin in increasing
intracellular levels of 13cisRA in cells incubated with ATRA (one-
way ANOVA F3,15¼0.315, P40.8) or 13cisRA (F3,12¼0.047,
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Figure 1 SH-SY5Y cells were incubated with acitretin (0–50mM) for
24h prior to the addition of 10mM ATRA (A)o r1 0mM 13cisRA (B) for a
further 24h. Values are expressed as intracellular retinoic acid (RA)
concentrations based on cell counts and cell volume calculations. Data are
mean values7s.e.m. from at least three separate experiments. Statistical
significance relative to controls without acitretin is indicated by *(Po0.05).
For the ANOVA with intracellular ATRA levels in (B)( F 3,13¼5.078,
P¼0.015), one outlier for the 10mM acitretin dose was removed
(studentised residual  2.682).
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medium from cells pretreated with or without 1–100mM acitretin
were not significantly different (ATRA incubations: 13cisRA levels
F3,8¼0.9, P¼0.46; ATRA levels F3,8¼1.35, P¼0.33 and 13cisRA
incubations: 13cisRA levels F3,8¼3.38, P¼0.08; ATRA levels
F3,8¼0.44, P¼0.73).
The effect of 50mM acitretin was also assessed in SH-SY5Y, SH-
EP, IMR-32 and NGP cell lines over a time course of 6–72h (data
not shown). In each cell line, peak intracellular ATRA concentra-
tions in the presence of acitretin were observed after 24h (Table 1).
However, in contrast to SH-SY5Y cells, where a selective increase
in intracellular ATRA concentrations was observed, pretreatment
of SH-EP, IMR-32 or NGP cells with acitretin, prior to incubation
with ATRA or 13cisRA, did not result in a significant increase in
either ATRA or 13cisRA intracellular levels (Table 1).
Analysis of CRABP expression
It was hypothesised that the responsiveness of tissue culture cell
lines to acitretin may correlate with CRABP expression and
therefore the relationship between CRABP expression and the
effect of acitretin on intracellular ATRA levels was evaluated.
Proteins detected by the CRABP I antibody (here referred to as
CRABP I) in SH-SY5Y, SH-EP, IMR-32 and NGP cells treated with
ATRA or 13cisRA (10mM) for 0–72h were evaluated by Western
blotting (Figure 2A). CRABP I expression was induced by ATRA
and 13cisRA in a time-dependent manner in SH-SY5Y, and
minimally in IMR-32 cells. Cellular retinoic acid binding protein I
expression was induced in NGP cells after treatment with either
ATRA or 13cisRA, although expression was also detected in
untreated cells. CRABP I was not detected in SH-EP cells after
incubation with either ATRA or 13cisRA. There was induction of
CRABP I expression in SH-SY5Y and IMR-32 cells treated with
50mM acitretin for 48h, but little induction in NGP cells and none
in SH-EP cells. Similar results were obtained using an antibody to
CRABP II (Figure 2B). These results suggest that the effect of
acitretin on intracellular ATRA levels reflected the induction of
expression of CRABP proteins in these cell lines, indicated by a
graph plotting CRABP I induction after 48h incubation with ATRA
or 13cisRA (10mM) against the mean increase in intracellular
ATRA concentration for each cell line from Table 1 (control
compared to acitretin-treated cells) (Figure 2C).
Effect of R116010 on intracellular retinoid concentrations
The effect of R116010 was examined in SH-SY5Y cells, a cell line
known to metabolise ATRA rapidly over 24h. Coincubation of
R116010 and either ATRA or 13cisRA in SH-SY5Y cells for 24h
significantly increased intracellular ATRA levels (one-way ANO-
VA, F2,15X11.5, Pp0.001), and this increase was approximately
linear with respect to R116010 dose (Linear contrasts, F1,15412,
Pp0.003; Figure 3A and B). Treatment with R116010 resulted in 2-
and 2.7-fold increases in ATRA concentrations from 95.2716.9
(mean7s.e.m.) mM with ATRA alone to 188719mM in the presence
of 1mM R116010 and 254.7731mM with 10mM R116010, respec-
tively (Figure 3A). After incubation with 13cisRA, R116010 gave
2.2- and 6.5-fold increases in intracellular ATRA concentrations
from 5.470.7mM with 13cisRA alone to 11.971.4 and 35.676.2mM
with 1 and 10mM R116010, respectively (Figure 3B). Conversely,
there was no effect of R116010 on intracellular 13cisRA
concentrations in cells incubated in ATRA or 13cisRA
(F2,15p2.213, PX0.144). Incubation with R116010 alone (1 and
10mM) did not result in concentrations of endogenous intracellular
retinoids above the lower limit of detection of the HPLC assay
(0.02–4mgml
 1).
Effect of acitretin and R116010 on cell proliferation
Retinoic acid has previously been shown to inhibit the growth of
NBL cells in culture. To determine whether the use of inhibitors of
RA metabolism could amplify this effect, the SRB assay was used to
assess the effect of acitretin and R116010 on SH-SY5Y cell
proliferation (Table 2). R116010 (1mM) had little effect on cell
growth, whereas acitretin (1mM) had a substantial effect, inhibiting
proliferation to 66.5 of control cell growth. The effect of acitretin
alone therefore masked any potentiation of RA-induced growth
inhibition. In contrast R116010 (1mM) potentiated the growth
inhibitory effects of ATRA and 13cisRA at concentrations of 0.01
and 0.1mM, respectively (one-way ANOVA hypothesis tests,
F1,27¼8.248, P¼0.008 for ATRA and F1,27¼17.579, Po0.001 for
13cisRA). However, the overall degree of potentiation by R116010
was relatively modest (from 60.3 to 48.9% for ATRA and from 53.8
to 42% for 13cisRA).
Effect of acitretin and R116010 on markers of retinoid
response
Retinoid response was evaluated in the SH-SY5Y cell line,
previously shown to have good induction of the retinoid
responsive genes, CRABP II and RARb (Veal et al, 2002). To
assess the transcriptional activity of increasing intracellular ATRA
concentrations, SH-SY5Y cells were transfected with the reporter
gene ‘secreted alkaline phosphatase’ (SEAP) under control of a
DR5 retinoic acid response element. The effect of acitretin or
Table 1 Intracellular retinoic acid concentrations following incubation with or without 50mM acitretin for 24h prior to the addition of 10mM ATRA or
13cisRA for a further 24h
a
ATRA incubation (lM) 13cisRA incubation (lM)
Cell line RA isomer Control Acitretin P
b Control Acitretin P
b
SH-SY5Y ATRA 39.177.4 113.5728.7 0.003 4.271.1 19.374.1 0.005
13cisRA 7.671.3 7.570.7 0.744 25.474.1 28.776.9 0.674
SH-EP ATRA 908.17378 10507439.3 0.652 49.9710.6 51.9718.2 0.933
13cisRA 43.579.1 39.9711.3 0.886 92.7719.7 75.7729.1 0.435
IMR-32 ATRA 354.6731.6 447.9783.6 0.382 59.9731.1 120.2766.2 0.707
13cisRA 29.772.5 26.571.6 0.352 39.4717.3 60.4714.6 0.378
NGP ATRA 613.37165.3 16577688.3 0.083 32.5715.2 21.471.4 0.642
13cisRA 46.0711.7 67.2723.4 0.41 84.6711.4 106.977.7 0.221
aResults are expressed as mean7s.e.m. from nX3 experiments.
bProbabilities from two-sided t-tests.
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sR116010 (1mM) in combination with ATRA or 13cisRA (0.1mM)
was studied after a 48h incubation period and analysed by two-
way ANOVA for retinoid effects and acitretin/R116010 effects
(Figure 4). Incubation with acitretin alone resulted in a five-fold
increase in SEAP expression (F1,43¼166.9, Po0.001). Incubation
with either ATRA or 13cisRA resulted in an 11-fold increase in
SEAP expression relative to untreated cells, but there was no
significant difference in response between ATRA and 13cisRA
(F1,43¼0.235, P¼0.63). R116010 alone had no effect on SEAP
expression. In the presence of acitretin, induction of SEAP
expression in response to ATRA or 13cisRA was significantly
reduced relative to the effects of these retinoids alone (F1,43¼8.83,
P¼0.005 and F1,43¼4.042, P¼0.05 for ATRA and 13cisRA,
respectively). This apparent antagonistic effect of acitretin was
also observed on CRABP II expression when comparing the effect
of ATRA alone and in combination with acitretin. Incubation with
SH-SY5Y
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Figure 2 CRABP I/II expression determined by Western blot analysis in SH-SY5Y, SH-EP and IMR-32 cells after 0–72h incubations with ATRA or
13cisRA (10mM)( A) and after 48h incubation with acitretin (Ac, 50mM)( B). b-Actin was used as a reference to correct for protein loading. (C) Graph
plotting CRABP I induction after 48h incubation with ATRA or 13cisRA (10mM) against the mean increase in intracellular ATRA concentration for each cell
line from Table 1 (control compared to acitretin treated cells).
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expression compared to untreated control cells, whereas ATRA in
combination with acitretin (10mM) induced a 3.5-fold increase in
expression, as determined by Western blot analysis (t6¼2.78,
P¼0.032).
All-trans retinoic acid or 13cisRA in combination with R116010
resulted in a 2.3- and 1.8-fold increase, respectively, in SEAP
expression relative to each RA alone (F1,43¼40.892, Po0.001 and
F1,43¼19.656, Po0.001 for ATRA and 13cisRA, respectively).
Although there was no difference between the SEAP induction seen
in response to ATRA compared to 13cisRA alone, the effect of
R116010 on SEAP induction in response to ATRA was greater than
that in response to 13cisRA (F1,43¼4.951, P¼0.031).
The expression of CYP26 may be an important marker of the
response of NBL cells to retinoids, both in vivo and in vitro, and
was measured using RT–PCR and real-time PCR. CYP26A1
expression was rapidly induced after incubation of cells with
ATRA or 13cisRA in a time- and concentration-dependent manner
(Figure 5A and B), with ATRA more potent than 13cisRA.
Incubation with acitretin (1mM) resulted in a marked induction
in CYP26A1 expression after 24h, which was not increased further
upon coincubation with either ATRA or 13cisRA (0.01mM,
Figure 5C). Incubation with R116010 alone (1mM) had no effect
on CYP26A1 expression, but R116010 (1mM) coincubated with
either ATRA or 13cisRA (both at concentrations of 0.01 and
0.1mM) significantly increased CYP26A1 expression compared to
retinoid alone after 24h (two-way ANOVA, effect of R116010
F1,32¼15.496, Po0.001). Compared to either retinoid alone,
R116010 enhanced CYP26A1 expression 6.8- and 1.7-fold with
0.01 and 0.1mM ATRA and 2.6- and 3.4-fold with 0.01 and 0.1mM
13cisRA (Figure 5D).
DISCUSSION
Resistance to RA treatment may be related to drug metabolism and
represents a significant clinical problem. Non-specific P450
inhibitors such as ketoconazole and liarozole can inhibit the
formation of metabolites of RA and can exert ATRA-mimetic
effects in vivo by enhancing endogenous plasma levels of ATRA
(Van Wauwe et al, 1988, 1992). However, one of the limitations to
the use of liarozole is its lack of specificity, and more selective
inhibitors of RA metabolism are needed (reviewed in Njar, 2002).
The current study was designed to determine whether agents that
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Figure 3 SH-SY5Y cells were coincubated with R116010 (0–10mM)
and either ATRA (A) or 13cisRA (B) (10mM) for 24h. Values are
expressed as intracellular retinoic acid (RA) concentrations based on cell
counts and cell volume calculations. Data plotted are mean values7s.e.m.
from at least four separate experiments. Statistical significance relative to
controls without R116010 is indicated by *** for Po0.001 and ** for
Po0.01.
Table 2 Measurement of the antiproliferative effect of ATRA and
13cisRA in the absence or presence of R116010 or acitretin in SH-SY5Y
cells
a
Incubation
RA isomer Inhibitor (1lM)
Growth inhibition (%
untreated cell growth)
R116010 96.472.4
Acitretin 66.571.9
0.01mM ATRA — 60.372.9
R116010 48.972.2
Acitretin 52.272.3
0.1mM 13cisRA — 53.872.5
R116010 4271.9
Acitretin 55.773.1
aResults are expressed as mean7s.e.m. from nX3 experiments.
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Figure 4 Induction of SEAP expression. SH-SY5Y cells were incubated
with ATRA or 13cisRA (0.1mM) for 48h in the absence or presence of
acitretin (Ac, 1mM) or R116010 (R, 1mM). Values are expressed as fold
increase relative to expression in untreated control cells. Data are mean
values7s.e.m. from at least three independent experiments. Statistical
significance from hypothesis tests in ANOVA is indicated by *** for
Po0.001, ** for Po0.01 and * for Po0.05.
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scan inhibit the metabolism of ATRA in NBL cells may be able to
increase the cellular response to RA.
It was hypothesised that high concentrations of acitretin may act
to reduce ATRA metabolism by binding to CRABP I, therefore
facilitating a greater availability of ATRA for binding to nuclear
receptors. Incubation of SH-SY5Y cells with acitretin resulted in a
concentration-dependent selective increase in intracellular ATRA
levels, after incubation with either ATRA or 13cisRA. Further
investigation in a panel of NBL cell lines revealed a mixed response
to preincubation with acitretin. There was a selective increase in
ATRA concentrations, but the degree of induction varied.
Evaluation of CRABP protein expression in these cell lines
demonstrated that CRABPs were expressed and could be induced
by RA in SH-SY5Y cells. There was significant expression of the
CRABPs in untreated NGP cells and this was further induced upon
incubation with RA. However, there was a relatively low level of
expression of CRABP in IMR-32 cells and none detected in SH-EP
cells. Correspondingly, ATRA concentrations in SH-SY5Y cells
increased significantly after pre-incubation with acitretin (50mM)
followed by either ATRA or 13cisRA. This effect was also observed
in IMR-32 and NGP cells, though the increases in intracellular
ATRA concentrations were not significant. This general trend
suggests that acitretin has a greater effect in cell lines that induce
expression of CRABPs, supporting the hypothesis that the acitretin
effects are mediated by CRABP I. However, the strong expression
of the CRABPs in the NGP cell line indicates that the contribution
of CRABP I in facilitating RA metabolism may vary between cell
lines.
Acitretin itself induced the expression of CRABPs, CYP26A1
mRNA and an RARE-reporter construct, and had significant anti-
proliferative effects in SH-SY5Y cells. Although acitretin binds
poorly to the RARs that mediate transcription, it has previously
been reported to activate RARs and to exert RA-mimetic effects
(Tian et al, 1997; Saurat, 1999).
It has been suggested that CRABP I over-expression may
increase initial intracellular RA concentrations (Chen et al, 2003).
Furthermore, over-expression of CRABP I can enhance the RA
induction of a reporter construct and cyclin D1 expression (Wei
et al, 1999; Blaese et al, 2003), while antisense oligonucleotides to
CRABP I partially inhibited the RA-induced expression of TGFb,
RARb and tenascin (Nugent and Greene, 1995). These observations
indicate that CRABP I may exert bi-phasic effects on both
intracellular RA concentrations and gene expression and suggest
a role for this protein in the facilitation of signal transduction prior
to any effect on RA degradation.
In SH-SY5Y cells transfected with RARE-SEAP, coincubation of
acitretin and either ATRA or 13cisRA resulted in a lower degree of
induction of SEAP expression compared to ATRA or 13cisRA
alone (Figure 4), which may be a consequence of acitretin binding
to either CRABP I or II. Supportive data were also obtained from
CRABP II analysis, where the induction of protein expression was
lower when comparing ATRA alone to ATRA in combination with
acitretin. Recent data indicate a role for CRABP II in the formation
of the RA–RAR complex, subsequently acting as a coactivator of
RAR-mediated transcription (Dong et al, 1999; Budhu and Noy,
2002). Acitretin binding to CRABP II may, in part, be responsible
Figure 5 Induction of CYP26A1 mRNA expression determined by RT–
PCR and real-time PCR. SH-SY5Y cells were treated with ATRA or
13cisRA for 24h at the concentrations indicated (A) or with a fixed
concentration of 1mM ATRA or 13cisRA for up to 72h (B). SH-SY5Y cells
were treated with ATRA or 13cisRA (0.01mM) for 24h in the absence or
presence of acitretin (Ac, 1mM) or R116010 (R, 1mM)( C). b-actin mRNA
expression was used to normalise the reverse transcription reaction.
Amplified products were analysed by agarose gel electrophoresis with
ethidium bromide staining. Reverse-transcribed RNA from SH-SY5Y cells
treated with ATRA or 13cisRA (0.01 or 0.1mM) for 24h in the absence or
presence R116010 (R, 1mM) was subjected to real-time PCR using TaqMan
probes for CYP26A1 and b-actin (D). Values are normalised for b-actin
levels and expressed as fold increase relative to expression of CYP26A1 in
cells treated with 0.01mM ATRA. Data are mean values7s.e.m. from at
least three independent experiments. Statistical significance from hypoth-
esis tests in ANOVA is indicated by * where F1,32¼5.714, Po0.05, and
*** where F1,32¼15.496, Po0.001.
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sfor the reduction of RA-responsive gene expression by preventing
CRABP II binding to the transcription complex. The ability of
acitretin to increase intracellular concentrations of ATRA appears
to override its capacity to stimulate the expression of proteins that
degrade RA. In spite of this, it has proved difficult to analyse a
biological downstream effect of increasing ATRA concentrations,
due to the RA-mimetic effects of acitretin itself. Based on these
data, it is possible that acitretin may provide a clinical benefit in
NBL. However, due to the complex nature of this interaction and
the more selective effects observed with R116010, further studies to
determine the mechanism of the interaction between acitretin and
RA would be necessary.
R116010 is an effective inhibitor of RA metabolism, with a 100-
fold greater potency compared to that of liarozole in intact human
breast T47D carcinoma cells. R116010 also has improved
specificity, suggesting it is less likely to produce adverse side-
effects. In vivo, R116010 itself inhibits the growth of murine
oestrogen-independent TA3-Ha mammary carcinoma tumours at
doses as low as 0.16mgkg
 1 and RA-like side effects are observed
at higher doses (5mgkg
 1) (Van heusden et al, 2002).
At concentrations of both 1 and 10mM, R116010 induced
significant increases in intracellular ATRA levels after incubation
of SH-SY5Y cells with either ATRA or 13cisRA, consistent with an
inhibition of ATRA metabolism. This increase was reflected in
enhanced RA-induced gene expression and inhibition of cell
proliferation when these cells were coincubated with R116010.
Induction of the RARE-SEAP reporter gene increased 2.3- and 1.8-
fold with ATRA and 13cisRA, respectively, in combination with
1mM R116010 compared to either agent alone, corresponding to
increasing intracellular ATRA concentrations. Additionally, RA
rapidly induced CYP26A1 expression in these cells, and this
response was significantly increased by coincubation with
R116010. Taken together, these data indicate that R116010 can
inhibit ATRA metabolism, which may lead to an enhanced
induction of retinoid responsive genes in human NBL cells in
vitro. However, these data do not exclude alternative mechanisms
of action for R116010.
It has previously been demonstrated that liarozole in combina-
tion with ATRA can partially reverse the decline of plasma ATRA
concentrations in patients, without increased toxicity (Miller et al,
1994). A similar elevation in plasma ATRA concentrations was
achieved with an intravenous (i.v.) administration of a liposomal
formulation of ATRA, implying that reducing ATRA metabolism
may be advantageous and potentially more effective for long-term
treatment (Estey et al, 1996; Ozpolat et al, 2003). The high degree
of interpatient variability in plasma 13cisRA concentrations
suggests that inhibitors of RA metabolism may be beneficial to
those patients with lower drug exposures. While changes
to 13cisRA dose may be one solution to this problem, the use
of agents such as R116010 may be more appropriate if lower
clinical exposures are a result of higher rates of RA metabolism.
Although two-fold increases in intracellular ATRA levels may not
markedly increase the antiproliferative effect of RA in NBL, there
may be a larger impact on other factors, such as the facilitation by
RA of tumour lysis by cytotoxic lymphocytes (Vertuani et al,
2003).
The relationship between RA sensitivity and RA turnover
appears to be complex, particularly following the identification
of the RA-inducible P450 enzymes, and it is likely that these events
are independently related to the expression of the RARs or other
intracellular molecules that mediate RA response. It is possible
that RA catabolism is an early event in the emergence of resistance
to retinoids, and may precede the selection of tumour cells
with modifications, such as MYCN amplification, that lead to
enhanced survival. Retinoic acid resistance has been extensively
studied in acute promyelocytic leukaemia, and many of these
observations may translate to NBL. The observations reported
here suggest a close link between induction of CYP26 and
RA-mediated responses. However, the augmentation of these
responses by R116010 is encouraging and points the way to further
optimization of retinoid treatment in preclinical and clinical
studies.
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